Cargando…

POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

Anthracyclines are among the most used chemotherapeutic agents in breast cancer (BC). However their use is hampered by anthracycline-induced cardiotoxicity (AIC). The currently known clinical and genetic risk factors do not fully explain the observed inter-individual variability and only have a limi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Velasco-Ruiz, Alejandro, Nuñez-Torres, Rocio, Pita, Guillermo, Wildiers, Hans, Lambrechts, Diether, Hatse, Sigrid, Delombaerde, Danielle, Van Brussel, Thomas, Alonso, M. Rosario, Alvarez, Nuria, Herraez, Belen, Vulsteke, Christof, Zamora, Pilar, Lopez-Fernandez, Teresa, Gonzalez-Neira, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622627/ https://www.ncbi.nlm.nih.gov/pubmed/34834357 http://dx.doi.org/10.3390/pharmaceutics13111942

Ejemplares similares

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors
por: Lambrechts, Yentl, et al.
Publicado: (2023)

A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact
por: Nunez-Torres, Rocio, et al.
Publicado: (2023)

POLRMT mutations impair mitochondrial transcription causing neurological disease
por: Oláhová, Monika, et al.
Publicado: (2021)

Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk
por: Gómez-Vecino, Aurora, et al.
Publicado: (2023)

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
por: Gómez-Vecino, Aurora, et al.
Publicado: (2023)

Cancer and Aging: Two Tightly Interconnected Biological Processes
por: Berben, Lieze, et al.
Publicado: (2021)

The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity
por: Ben Abdallah, Ichrak, et al.
Publicado: (2020)

Targeting Mitochondrial Metabolism and RNA Polymerase POLRMT to Overcome Multidrug Resistance in Cancer
por: Yu, Hui-Jing, et al.
Publicado: (2021)

Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer
por: Li, Xiaojun, et al.
Publicado: (2023)

The mitochondrial RNA polymerase POLRMT promotes skin squamous cell carcinoma cell growth
por: Wang, Yulong, et al.
Publicado: (2022)

The footprint of the ageing stroma in older patients with breast cancer
por: Brouwers, Barbara, et al.
Publicado: (2017)

Clinical Application of the Heart Rate Deceleration Capacity Test to Predict Epirubicin-induced Cardiotoxicity
por: Feng, Yan-ying, et al.
Publicado: (2015)

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
por: Yang, Fang, et al.
Publicado: (2017)

Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study
por: Li, Xiaofang, et al.
Publicado: (2022)

POLRMT regulates the switch between replication primer formation and gene expression of mammalian mtDNA
por: Kühl, Inge, et al.
Publicado: (2016)

Targeting Mitochondrial DNA Transcription by POLRMT Inhibition or Depletion as a Potential Strategy for Cancer Treatment
por: Daglish, Sabrina C. D., et al.
Publicado: (2023)

A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth
por: Li, Shu-ping, et al.
Publicado: (2023)

Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report
por: Delombaerde, Danielle, et al.
Publicado: (2022)

Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status
por: Hatse, Sigrid, et al.
Publicado: (2014)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Circulating biomarkers at diagnosis correlate with distant metastases of early luminal-like breast cancer
por: Lambrechts, Yentl, et al.
Publicado: (2023)

POLRMT over‐expression is linked to WNT/beta‐catenin signaling, immune infiltration, and unfavorable outcomes in lung adenocarcinoma patients
por: Huang, Yongkang, et al.
Publicado: (2023)

Blocking Store-Operated Ca(2+) Entry to Protect HL-1 Cardiomyocytes from Epirubicin-Induced Cardiotoxicity
por: Liu, Xian, et al.
Publicado: (2023)

Length heterogeneity at conserved sequence block 2 in human mitochondrial DNA acts as a rheostat for RNA polymerase POLRMT activity
por: Tan, Benedict G., et al.
Publicado: (2016)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

The Role of Abdominal Surgery in Refractory Immune Checkpoint Inhibitor Enterocolitis: A Case Report
por: Verhé, Manon, et al.
Publicado: (2023)

Paternal Inheritance of Bisphenol A Cardiotoxic Effects: The Implications of Sperm Epigenome
por: Lombó, Marta, et al.
Publicado: (2021)

Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
por: Li, Hai, et al.
Publicado: (2019)

Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy
por: Delombaerde, D., et al.
Publicado: (2021)

Blood Immunosenescence Signatures Reflecting Age, Frailty and Tumor Immune Infiltrate in Patients with Early Luminal Breast Cancer
por: Berben, Lieze, et al.
Publicado: (2021)

Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty
por: Bailur, Jithendra Kini, et al.
Publicado: (2017)

Biological ageing and frailty markers in breast cancer patients
por: Brouwers, Barbara, et al.
Publicado: (2015)

Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy
por: Dalmasso, Bruna, et al.
Publicado: (2018)

Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study
por: Wu, Qi, et al.
Publicado: (2022)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study
por: Delombaerde, Danielle, et al.
Publicado: (2023)

Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)

Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature
por: Framarino-dei-Malatesta, Marialuisa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v49av4l2bd4hgi8kbntr79a2bm